Action XERS XERIS BIOPHARMA HOLDINGS, INC.
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription

Autres langues Xeris Biopharma Holdings, Inc.

Actions

XERS

US98422E1038

Temps réel estimé Cboe BZX
Autres places de cotation
 18:18:20 16/04/2024 		Varia. 5j. Varia. 1 janv.
1,835 USD -0,81 % Graphique intraday de Xeris Biopharma Holdings, Inc. -8,91 % -21,70 %
28/03 XERIS BIOPHARMA HOLDINGS, INC. : Oppenheimer passe à l'achat ZM
06/03 Transcript : Xeris Biopharma Holdings, Inc., Q4 2023 Earnings Call, Mar 06, 2024

Autres langues

Recherche
Voir les résultats
Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !
Inscription 100% Gratuite
Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Xeris Biopharma to Participate in the 23rd Annual Needham Virtual Healthcare Conference
Xeris Biopharma Holdings, Inc.(NasdaqGS:XERS) added to S&P Pharmaceuticals Select Industry Index
Xeris Biopharma: Q4 Earnings Snapshot
Earnings Flash (XERS) XERIS BIOPHARMA HOLDINGS Reports Q4 Revenue $44.4M, vs. Street Est of $43.6M
Xeris Biopharma Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Events
Xeris Refinances Its $150M Senior Secured Term Loan Facility With Hayfin Capital
Xeris Biopharma Holdings, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
Xeris Biopharma Holdings, Inc. Provides Earnings Guidance for the Year 2024
Xeris Refinances its $150 Million Senior Secured Term Loan Facility with Hayfin Capital
North American Morning Briefing : Stock Futures -2-
Xeris Biopharma to Report Fourth Quarter and Full Year 2023 Financial Results on March 6, 2024
Xeris to Present at the Oppenheimer 34th Annual Healthcare Life Science Conference
Xeris Biopharma Holdings Seeks Acquisitions
US Equity Markets Close Higher Wednesday as Investors Await Inflation Data
Sector Update: Health Care Stocks Gain Late Afternoon
Xeris Biopharma Shares Rise on Licensing Agreement With Amgen
Xeris Biopharma Shares Climb 12% on Amgen License Agreement
Xeris Biopharma Reaches License Agreement With Amgen On Thyroid Eye Disease Treatment
Xeris Biopharma Enters Into an Exclusive Worldwide License Agreement for Xeriject® Formulation of Teprotumumab
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action XERS
  4. Actualités Xeris Biopharma Holdings, Inc.
  5. Autres langues